Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies, we are revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health. Through tireless efforts, breakthrough molecular science and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work – the patient.”
David Dean Halbert
Chairman, Founder and CEO
Caris Life Sciences
As the pioneer in precision medicine, Caris is ushering in a new era of cancer care with blood-based monitoring for patients before treatment, during treatment and after treatment. Currently available within Caris’ Precision Oncology Alliance, our pan-cancer, circulating nucleic acids sequencing (cNAS) assay combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
We are also advancing precision medicine through advanced artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN™, across our extensive catalog of molecular intelligence and clinical outcomes data, Caris is actively developing a better understanding of the molecular mechanisms of cancer in ways never before possible. This information provides an unmatched resource to help physicians better identify and predict patient response to therapy, as well as support researchers and biopharmaceutical companies derive unique insights for research development, clinical trials and target identification.
Matched Dataset with Outcomes
Precision Oncology Alliance Members
Active Biopharma Partnerships
Square Feet of Laboratory Space
Large facility footprint – 411,000 sq. ft. globally.
Caris has a unique combination of expertise, proprietary technologies, clinical testing abilities, and a vast library of data – molecular data as well as outcomes data on hundreds of thousands of patients – that allows us to advance precision medicine in ways that other companies cannot. We have developed market-leading platforms that are helping clinicians better diagnose and treat their patients today and accelerate the discoveries of tomorrow.
For questions about Caris molecular profiling please contact us.